Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

3M Aims For Acelity In $6.7Bn Deal To Expand Wound-Care Presence

Executive Summary

3M is betting big on wound-care maker Acelity and paying $6.7bn to buy the company and its KCI subsidiaries in its largest acquisition to date. 

You may also be interested in...



3M Plans To Spin Off Health Care Business By The End Of 2023

The company’s health businesses include product lines worth nearly $9bn in annual sales. The deal is designed to allow both the new health care company and the “new 3M” to focus resources more efficiently on their separate priorities.

Device/Diagnostics Quarterly Dealmaking Statistics, Q2 2019

Device financing totaled $2.3bn for Q2 2019, with the debt category bringing in the most money. Merger and acquisition deals reached an aggregate $9.1bn (a 25% increase from Q1), thanks mostly to 3M’s  $6.7bn takeover of Acelity and its KCI subsidiaries. Diagnostics/research financing, which totaled $2.4bn, showed a significant rise from the previous quarter, while diagnostics/research tools M&A values, at $233m, exhibited a steep decline.

KCI's Prevena Becomes First FDA-Cleared Negative Pressure Wound-Closure Device

The US FDA granted KCI's de novo request for the Prevena incision management system, making it the first negative pressure device cleared for reducing superficial surgical site infections in patients at high risk.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT125047

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel